Summary
An interactive network comprised of neuropeptide Y (NPY) and cohorts is obligatory in the hypothalamic integration of appetite and energy expenditure on a minute-to-minute basis. High or low abundance of NPY and cognate receptors dysregulates the homeostatic milieu engendering hyperphagia, decreased energy expenditure, obesity and attendant metabolic syndrome cluster of dyslipidemia, glucose intolerance, insulin resistance and hyperinsulinemia, risk factors for type II diabetes and cardiovascular diseases. Increasing the supply of the endogenous repressor hormone leptin locally in the hypothalamus with the aid of leptin gene therapy, blocked age-related and dietary obesities, and the sequential development of dyslipidemia, hyperglycemia, and insulin resistance. Thus, sustained repression of NPY signaling with increased leptin selectively in the hypothalamus can avert environmental obesity and the risks of metabolic diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Stein CJ, Colditz GA (2004) The epidemic of obesity. J Clin Endocrinol Metab 89: 2522–2525
Slyper AH (2004) The pediatric obesity epidemic: causes and controversies. J Clin Endocrinol Metab 89: 2540–2547
Kalra SP, Kalra PS (2003) Keeping obesity and metabolic syndrome at bay with central leptin and cytokine gene therapy. In: I Hamilton (ed.): Current Medicinal Chemistry — Central Nervous System Agent. Bentham Science Publishers Ltd, San Francisco, CA, 189–199
Kalra SP, Kalra PS (2005) Gene transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life-expectancy. Trends Pharmacol Sci 26: in press
Grundy SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89: 2595–2600
Carr MC, Brunzell JD (2004) Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89: 2601–2607
Hill JO, Wyatt HR, Reed GW, Peters JC (2003) Obesity and the environment: where do we go from here? Science 299: 853–855
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348: 1625–1638
Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120: 701–713
Loureiro ML (2004) Obesity: Economic Dimensions of a “Super Size” Problem. Choices 35–39
Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS (2005) A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352: 1138–1145
Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20: 68–100
Dhillon H, Ge Y, Minter RM, Prima V, Moldawer LL, Muzyczka N, Zolotukhin S, Kalra PS, Kalra SP (2000) Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. Relationship with body weight change. Regul Pept 92: 97–105
Horvath TL, Diano S, Tschop M (2004) Brain circuits regulating energy homeostasis. Neuroscientist 10: 235–246
Kalra SP, Bagnasco M, Otukonyong EE, Dube MG, Kalra PS (2003) Rhythmic, reciprocal ghrelin and leptin signaling: new insight in the development of obesity. Regul Pept 111: 1–11
Kalra SP, Kalra PS (2004) NPY and cohorts in regulating appetite, obesity and metabolic syndrome: Beneficial effects of gene therapy. Neuropeptides 38: 201–211
Kalra SP, Kalra PS (2004) NPY — an endearing journey in search of a neurochemical on/off switch for appetite, sex and reproduction. Peptides 25: 465–471
Kalra SP, Kalra PS (2004) NPY: A Novel on/off switch for control of appetite and reproduction. In: MC Michel (ed.): Neuropeptide Y and Related Peptides. Springer-Verlag, Berlin, 221–249
Kalra SP, Kalra PS (2003) Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine 22: 49–55
Kalra PS, Kalra SP (2002) Obesity and Metabolic Syndrome: Long-term benefits of central leptin gene therapy. In: JR Prous (ed.): Drugs of Today. Prous Science, Barcelona, Spain, 745–757
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548–2556
Unger RH (2002) Lipotoxic diseases. Annu Rev Med 53: 319–336
Morash B, Li A, Murphy PR, Wilkinson M, Ur E (1999) Leptin gene expression in the brain and pituitary gland. Endocrinology 140: 5995–5998
Pu S, Kalra PS, Kalra SP (1998) Diurnal rhythm in cyclic GMP/nitric oxide efflux in the medial preoptic area of male rats. Brain Res 808: 310–312
Bagnasco M, Kalra PS, Kalra SP (2002) Plasma leptin levels are pulsatile in adult rats: effects of gonadectomy. Neuroendocrinology 75: 257–263
Bagnasco M, Kalra PS, Kalra SP (2002) Ghrelin and leptin pulse discharge in fed and fasted rats. Endocrinology 143: 726–729
Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP (2005) High fat diet-induced ultradian leptin and insulin hypersecretion and ghrelin is absent in obesity-resistant rats. Obesity Research 13: 991–999
Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP (2005) Central leptin differentially modulates ultradian secretory patterns of insulin, leptin and ghrelin independent of effects on food intake and body weight. Peptides 26, in press
Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS (1991) Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA 88: 10931–10935
Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P, Friedman JM (2001) Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 108: 1113–1121
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903–908
Kalra PS, Dube MG, Xu B, Kalra SP (1997) Increased receptor sensitivity to neuropeptide Y in the hypothalamus may underlie transient hyperphagia and body weight gain. Regul Pept 72: 121–130
Kalra PS, Dube MG, Xu B, Farmerie WG, Kalra SP (1998) Neuropeptide Y (NPY) Y1 receptor mRNA is upregulated in association with transient hyperphagia and body weight gain: evidence for a hypothalamic site for concurrent development of leptin resistance. J Neuroendocrinol 10: 43–49
Ueno N, Dube MG, Inui A, Kalra PS, Kalra SP (2004) Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology 145: 4176–4184
Kalra SP, Ueno N, Kalra PS (2005) Stimulation of appetite by ghrelin is regulated by leptin restraint: peripheral and central sites of action. J Nutr 135: 1331–1335
Dhillon H, Kalra SP, Kalra PS (2001) Dose-dependent effects of central leptin gene therapy on genes that regulate body weight and appetite in the hypothalamus. Mol Ther 4: 139–145
Billington CJ, Briggs JE, Grace M, Levine AS. (1991) Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 260: R321–R327
Bagnasco M, Dube MG, Kalra PS, Kalra SP (2002) Evidence for the existence of distinct central appetite and energy expenditure pathways and stimulation of ghrelin as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology 143: 4409–4421
Bowers RR, Festuccia WT, Song CK, Shi H, Migliorini RH, Bartness TJ (2004) Sympathetic innervation of white adipose tissue and its regulation of fat cell number. Am J Physiol Regul Integr Comp Physiol 286: R1167–1175
Chen XM, Hosono T, Yoda T, Fukuda Y, Kanosue K (1998) Efferent projection from the preoptic area for the control of non-shivering thermogenesis in rats. J Physiol 512: 883–892
Hermens WT, Verhaagen J (1998) Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol 55: 399–432
Carter BJ, Burstein H (2004) Adeno-associated virus and AAV vectors for gene delivery. In: N Templeton-Smith (ed.): Theruapeutics Mechanisms and Strategies. Marcel Dekker, New York, NY, 71–1011
Dhillon H, Kalra SP, Prima V, Zolotukhin S, Scarpace PJ, Moldawer LL, Muzyczka N, Kalra PS (2001) Central leptin gene therapy suppresses body weight gain, adiposity and serum insulin without affecting food consumption in normal rats: A long-term study. Regul Pept 99: 69–77
Beretta E, Dube MG, Kalra PS, Kalra SP (2002) Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: Effects on serum ghrelin and appetite-regulating genes. Ped Res 52: 189–198
Boghossian S, Lecklin AH, Torto R, Kalra PS, Kalra SP (2005) Suppression of fat deposition for the life time of rodents with gene therapy. Peptides 26: 1512–1519
Lecklin AH, Dube MG, Torto R, Kalra PS, Kalra SP (2005) Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation. Peptides 26: 1176–1187
Beretta E, Dube MG, Kalra PS, Kalra SP (2002) Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods. Peptides 23: 875–984
Kalra SP (2001) Circumventing leptin resistance for weight control. Proc Natl Acad Sci USA 98: 4279–4281
Kalra SP, Kalra PS (2001) Viral vectors as probes to decipher brain circuitry for weight control. Trends Endocrinol Metab 12: 377–378
Dube MG, Beretta E, Dhillon H, Ueno N, Kalra PS, Kalra SP (2002) Central leptin gene therapy blocks high fat diet-induced weight gain, hyperleptinemia and hyperinsulinemia: effects on serum ghrelin levels. Diabetes 51: 1729–1736
Ueno N, Dube MG, Kalra PS, Kalra SP (2002) Central leptin gene therapy increases insulin sensitivity and suppresses weight without affecting food intake. Annual Society for Neuroscience, October 23–27, Abs #573.9, pp 781
Kalra SP, Ueno N, Boghossian S, Kalra PS (2004) Leptin transgene expression in the hypothalamus reduces mortality and increases lifespan. Annual Society for Neuroscience, October 23–27, pp M–103, Abs #565.15
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Kalra, S.P., Kalra, P.S. (2006). Subjugation of hypothalamic NPY and cohorts with central leptin gene therapy alleviates dyslipidemia, insulin resistance, and obesity for life-time. In: Zukowska, Z., Feuerstein, G.Z. (eds) NPY Family of Peptides in Neurobiology, Cardiovascular and Metabolic Disorders: from Genes to Therapeutics. Experientia Supplementum, vol 95. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7417-9_12
Download citation
DOI: https://doi.org/10.1007/3-7643-7417-9_12
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7155-5
Online ISBN: 978-3-7643-7417-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)